Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence

• Main Authors: Anastasiya A. Kobelyatskaya, Elena A. Pudova, Anastasiya V. Snezhkina, Maria S. Fedorova, Vladislav S. Pavlov, Zulfiya G. Guvatova, Maria V. Savvateeva, Nataliya V. Melnikova, Alexey A. Dmitriev, Dmitry Y. Trofimov, Gennady T. Sukhikh, Kirill M. Nyushko, Boris Y. Alekseev, Sergey V. Razin, George S. Krasnov, Anna V. Kudryavtseva
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Life
• Subjects: prostate cancer; TMPRSS2–ERG molecular subtype; tumor recurrence; gene expression; RNA–Seq
• Online Access: https://www.mdpi.com/2075-1729/11/6/588

Currently, seven molecular subtypes of prostate cancer (PCa) are known, the most common of which being the subtype characterized by the presence of the TMPRSS2–ERG fusion transcript. While there is a considerable amount of work devoted to the influence of this transcript on the prognosis of the disease, data on its role in the progression and prognosis of PCa remain controversial. The present study is devoted to the analysis of the association between the TMPRSS2–ERG transcript and the biochemical recurrence of PCa. The study included two cohorts: the RNA–Seq sample of Russian patients with PCa (<i>n</i> = 72) and the TCGA–PRAD data (<i>n</i> = 203). The results of the analysis of the association between the TMPRSS2–ERG transcript and biochemical recurrence were contradictory. The differential expression analysis (biochemical recurrence cases versus biochemical recurrence-free) and the gene set enrichment analysis revealed a list of genes involved in major cellular pathways. The <i>GNL3</i>, <i>QSOX2</i>, <i>SSPO</i>, and <i>SYS1</i> genes were selected as predictors of the potential prognostic model (AUC = 1.000 for a cohort of Russian patients with PCa and AUC = 0.779 for a TCGA–PRAD cohort).